Two-year visual results for older asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization.
Claudio
C
Campa
Simon P
SP
Harding
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D044466:Asian People / Q000208:ethnology; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D007564:Japan / Q000453:epidemiology; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D010778:Photochemotherapy; D019233:Retreatment; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*; D014822:Vitreous Body; D016387:Women's Health
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab